Takeda Bolsters IBD Pipeline by Partnering with Prometheus Biosciences

By Subham Nandi

Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)

Published: 26 Oct-2019

DOI: 10.3833/pdr.v2019.i10.2465     ISSN: 1756-7874

Section: Licensing



Takeda has partnered with US-based Prometheus Biosciences to develop and commercialise therapies for inflammatory bowel disease (IBD) in a deal worth more than US$420 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details